Financial Performance - The company's operating revenue for 2022 was ¥627,364,047.52, representing a 22.09% increase compared to ¥513,837,362.93 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥132,304,592.95, a 15.07% increase from ¥114,978,156.78 in 2021[25]. - The net cash flow from operating activities increased by 68.80% to ¥82,845,438.18 in 2022, up from ¥49,078,585.36 in 2021[25]. - The total assets at the end of 2022 reached ¥1,533,773,003.80, a significant increase of 129.64% from ¥667,902,377.53 at the end of 2021[25]. - The net assets attributable to shareholders increased by 236.85% to ¥1,355,941,510.33 at the end of 2022, compared to ¥402,530,592.37 at the end of 2021[25]. - The company reported a basic earnings per share of ¥1.29 for 2022, up 12.17% from ¥1.15 in 2021[25]. - Total revenue for 2022 reached ¥627,364,047.52, representing a year-on-year increase of 22.09% compared to ¥513,837,362.93 in 2021[57]. - The pharmaceutical intermediates segment generated ¥621,211,163.02, accounting for 99.02% of total revenue, with a year-on-year growth of 22.06%[57]. - Sales from the L-phenylalanine series products amounted to ¥551,419,588.75, which is 87.90% of total revenue, reflecting a 23.24% increase from ¥447,421,877.36 in 2021[57]. - Domestic sales contributed ¥611,266,891.71, representing 97.43% of total revenue, with a year-on-year growth of 22.23%[57]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares (including tax) to all shareholders based on a total of 133,360,000 shares[3]. - The total distributable profit for the year is 361,203,157.45 CNY, with cash dividends accounting for 100% of the profit distribution[141]. - The company will prioritize cash dividends, with a minimum of 10% of the distributable profits allocated for cash distribution if there are no major investment plans[186]. - The company plans to distribute cash dividends with a minimum ratio of 80% for mature stages without major capital expenditures, 40% for mature stages with major expenditures, and 20% for growth stages with major expenditures[187]. - The company aims to maintain a stable profit distribution policy that balances investor returns with long-term growth[185]. Research and Development - The company has a dedicated R&D team of 152 technical personnel, accounting for 19% of its total workforce, equipped with advanced research and analysis instruments[54]. - The company has developed core technologies in the preparation of L-tyrosine, p-toluenesulfonic acid, and green production processes, which have led to continuous improvements in product quality and cost reduction[50]. - Research and development expenses increased by 45.72% to ¥30,002,237.05, primarily due to higher R&D investments[64]. - The company's R&D investment in 2022 amounted to ¥30,002,237.05, representing 4.78% of total revenue, an increase from 4.01% in 2021[66]. - The number of R&D personnel increased by 60% from 95 in 2021 to 152 in 2022, with a notable rise in master's degree holders by 200%[66]. Market Position and Strategy - The global pharmaceutical market is projected to grow at a compound annual growth rate (CAGR) of 5.67% from 2020 to 2025[34]. - The Chinese pharmaceutical market is expected to reach ¥22,873 billion by 2025, growing from ¥17,292 billion in 2021[34]. - The company is positioned to benefit from the increasing demand for specialty APIs and the ongoing reforms in the Chinese healthcare system[35]. - The CMO/CDMO market in China is projected to maintain a compound annual growth rate of over 18%, reaching a market size exceeding 120 billion yuan by 2025[37]. - The company plans to focus on the development of specialty APIs and intermediates, aiming to become a distinctive production base for APIs[92]. Governance and Compliance - The company emphasizes strict governance and compliance with laws and regulations, ensuring shareholder rights are protected during meetings[102]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[104]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, and operations, ensuring autonomous business capabilities[110]. - The company has established a transparent performance evaluation and incentive mechanism for its management team[107]. - The company has a complete independent labor, personnel, and salary management system, ensuring no salary payments are made by related parties[111]. Environmental Responsibility - The company has obtained multiple environmental permits, including a hazardous chemicals safety use permit valid until May 30, 2023[151]. - The company achieved a total wastewater discharge of 38 tons of nitrogen, which is compliant with industry standards[153]. - The company has implemented various environmental protection laws and standards in its operations[151]. - The company has maintained compliance with all relevant environmental regulations and standards[151]. - The company invested a total of 45.53 million yuan in environmental governance and protection during the reporting period, with an environmental protection tax of 44,900 yuan[162]. Risks and Challenges - The company is facing innovation risks with 15 API and 2 formulation projects under development, which may impact profitability if not successful[96]. - The company relies heavily on the sales of L-tyrosine series products, which contribute over 80% to its revenue, posing a risk if demand decreases[97]. - The pharmaceutical industry, which is the company's main customer base, is under pressure from national policies that may lower drug prices, impacting future profitability[98]. - The company faces environmental risks due to potential non-compliance with waste discharge regulations, which may lead to increased operational costs in the short term[98]. - Safety production risks are present as the company handles flammable and toxic materials, with potential for increased safety investment due to stricter future regulations[98]. Employee and Management - The total number of employees at the end of the reporting period is 800, with 765 in the parent company and 35 in major subsidiaries[137]. - The professional composition includes 544 production personnel, 16 sales personnel, 152 technical personnel, 10 financial personnel, and 78 administrative personnel[137]. - The company has implemented a competitive compensation policy that includes salaries, benefits, and performance bonuses[138]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.2681 million[128]. - The company plans to enhance its performance evaluation system, linking assessment results to compensation to motivate employees[138]. Shareholder Engagement - The company held two shareholder meetings during the reporting period, with the first on March 4, 2022, and the second on December 19, 2022, with a participation rate of 74.99% in the latter[114]. - The company will ensure that any shareholder who has misappropriated funds will have their dividends deducted to repay the amount owed[185]. - The company commits to transparency and accountability in its financial disclosures, ensuring no misleading statements are made[194]. - The company will disclose its profit distribution plans and retained earnings usage in regular reports[186]. - The company will conduct a review of its shareholder return plan every three years, incorporating feedback from shareholders and independent directors[191]. Future Outlook - The company plans to focus on the development of specialty APIs and intermediates, aiming to become a distinctive production base for APIs[92]. - In 2023, the company aims to leverage its fundraising advantages to invest in essential pharmaceutical projects, enhancing its technical capabilities and attracting top talent[93]. - The company will implement a performance management system linking employee performance to compensation to support annual goals[95]. - The company plans to expand its market presence and enhance product development in the upcoming fiscal year[125]. - The company will prioritize cash dividends while ensuring normal operations and development needs are met in the next three years[189].

证券代码：301277 证券简称：新天地 公告编号：2023-030 河南新天地药业股份有限公司（以下简称"公司"）已于2023年3月31日 披露了公司《2022年年度报告》及其摘要，详情请参阅《证券时报》、《证 券日报》、《中国证券报》、《上海证券报》及巨潮资讯网（www.cninfo.co m.cn）。为了更好地与广大投资者进行交流，使投资者能够进一步了解公司的 生产经营情况，公司定于2023年4月21日（星期五）15:00-16:30举行2022年度 业绩网上说明会，具体情况如下： 会议召开方式：网络文字互动 会议召开时间：2023年4月21日（星期五）15:00-16:30 （一）问题征集 投资者可于2023年4月21日（星期五）15:00前登录http://ir.p5w.net/zj/或扫 描下方二维码，进入问题征集专题页面。公司将在2022年度业绩说明会上， 对投资者普遍关注的问题进行回答。 1 河南新天地药业股份有限公司 关于举办2022年度业绩网上说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 （二）在线参与 投资者可于2023 ...